MentiNova, Inc., is exploring an oral medication that could reduce the uncontrollable, often chaotic movements in patients being treated with L-Dopa. MentiNova's focus at this time is to use a drug that is currently clinically approved and repurpose it for the treatment of LID in patients with Parkinson's disease.
